Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493984 | 0.90 | BRD4 (0.39) | BRD4AURKAAURKB | |
| SCHEMBL4504140 | 0.90 | BRD4 (0.36) | BRD4AURKAAURKB | |
| SCHEMBL4504227 | 0.90 | BRD4 (0.37) | BRD4AURKAAURKBPTGER4 | |
| SCHEMBL4501413 | 0.88 | BRD4 (0.36) | BRD4AURKAAURKB | |
| SCHEMBL4506965 | 0.85 | BRD4 (0.37) | BRD4AURKAAURKBNPC1PTGER4 | |
| SCHEMBL4492358 | 0.83 | SMN1; SMN2 (0.37) | BRD4NPC1 | |
| SCHEMBL4492355 | 0.83 | SMN1; SMN2 (0.37) | BRD4NPC1 | |
| Benzene SCHEMBL4493992 | 0.83 | BRD4 (0.39) | BRD4AURKAAURKB | |
| SCHEMBL5249126 | 0.74 | KDM4E (0.39) | NPC1 | |
| SCHEMBL5518836 | 0.73 | KDM4E (0.44) | NPC1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | GEORGES GUY | 2009-11-26 | — | — | US | disclosed |
| EP-2001882-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-La Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| EP-1968932-A1 | PROCESS FOR PREPARING CINACALCET | Teva Pharmaceutical Industries Ltd. (IL) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008063645-A1 | PROCESS FOR PREPARING CINACALCET | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007107346-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A43, CYP3A5, CYP3A7 | BRD4 1830/4885AURKA 1558/4885AURKB 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.